• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views

    4/17/24 2:34:59 PM ET
    $EDBL
    $INVO
    $LGVN
    $OTRK
    Farming/Seeds/Milling
    Consumer Staples
    Medical/Dental Instruments
    Health Care
    Get the next $EDBL alert in real time by email

    U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday.

    The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17.

    Check This Out: Alphabet, Toll Brothers And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Utilities shares rose by 1.5% on Wednesday.

    In trading on Wednesday, information technology shares fell by 1.1%.

     

    Top Headline

     

    U.S. Bancorp (NYSE:USB) reported upbeat first-quarter FY24 earnings on Wednesday.

    Revenue stood at $6.7 billion (-6.4% Y/Y), which aligns with the consensus. Adjusted earnings per share came in at 90 cents, beating the consensus of 88 cents.

     

    Equities Trading UP

     

    INVO Bioscience, Inc. (NASDAQ:INVO) shares shot up 218% to $2.4592 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024.

    Shares of Edible Garden AG Incorporated (NASDAQ:EDBL) got a boost, surging 89% to $8.60 after the company reported preliminary first quarter fy24 results.

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were also up, gaining 30% to $5.28 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider.

     

    Equities Trading DOWN

     

    Longeveron Inc. (NASDAQ:LGVN) shares dropped 38% to $2.1750 after the company announced the exercise of warrants for $6.2 million in gross proceeds.

    Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) were down 19% to $12.63. The company announced topline results from Phase 2 PRECEDENT study of dalzanemdor for the treatment of people with mild cognitive impairment in Parkinson's Disease.

    Ontrak, Inc. (NASDAQ:OTRK) was down, falling 21% to $0.3651 after the company reported worse-than-expected quarterly financial results.

    Also Check This Out: How To Earn $500 A Month From Intel Stock Ahead Of Q1 Earnings

     

    Commodities

     

    In commodity news, oil traded down 3% to $82.78 while gold traded down 0.8% at $2,388.70.

    Silver traded up 0.2% to $28.42 on Wednesday, while copper rose 0.8% to $4.3395.

     

    Euro zone

     

    European shares closed higher today. The eurozone’s STOXX 600 gained 0.06%, London’s FTSE 100 rose 0.35% while Spain’s IBEX 35 Index gained 1.02% The German DAX gained 0.02% French CAC 40 climbed 0.62% while Italy’s FTSE MIB Index gained 0.72%.

    The consumer price inflation rate in the Eurozone came in at 2.4% year-over-year in March. The UK’s inflation rate eased to 3.2% year-over-year in March versus 3.4% in the prior month, while producer prices increased 0.6% year-over-year in March.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Wednesday, with Japan’s Nikkei 225 falling 1.32%, Hong Kong’s Hang Seng Index gaining 0.02% and China’s Shanghai Composite gaining 2.14%.

    Japan recorded a trade surplus of JPY 366,467 billion in March versus a deficit of JPY 750,854 billion in the year-ago period, while the Reuters Tankan sentiment index for manufacturers declined to +9 in April versus March’s reading of +10.

     

    Economics

     

    U.S. mortgage applications climbed by 3.3% in the latest week.

    Crude oil inventories in the U.S. climbed by 2.735 million barrels in the week ended April 12, compared to a 5.841 million gain in previous prior week.

    Now Read This: Top 5 Tech And Telecom Stocks That May Rocket Higher This Month

     

    Get the next $EDBL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDBL
    $INVO
    $LGVN
    $OTRK

    CompanyDatePrice TargetRatingAnalyst
    U.S. Bancorp
    $USB
    1/7/2026Outperform → Peer Perform
    Wolfe Research
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    U.S. Bancorp
    $USB
    10/23/2025$52.50Hold → Buy
    Deutsche Bank
    U.S. Bancorp
    $USB
    9/29/2025$56.00Overweight → Equal-Weight
    Morgan Stanley
    U.S. Bancorp
    $USB
    7/7/2025$57.00Outperform → Strong Buy
    Raymond James
    U.S. Bancorp
    $USB
    5/15/2025$60.00Buy
    TD Cowen
    U.S. Bancorp
    $USB
    4/3/2025$43.50Neutral → Underweight
    Analyst
    U.S. Bancorp
    $USB
    4/3/2025$49.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elavon Wins Multiple Top Payment Gateway Awards

    Fusebox gateway recognized for 7th consecutive year by TSG Elavon, a wholly owned subsidiary of U.S. Bank and one of the world's largest payment processors, is proud to be recognized with several performance honors in the 2026 Real Transaction Metrics Awards presented by TSG, a globally recognized analytics, intelligence, and solutions-focused firm serving the payments ecosystem. These awards highlight payment gateways that consistently deliver excellence across the performance areas that matter most to merchants and their customers. Elavon's Fusebox gateway received two first place awards for Best Performing Gateway and Best Transaction Speed while earning runner up honors for Highest

    2/11/26 10:00:00 AM ET
    $USB
    Major Banks
    Finance

    $EDBL
    $INVO
    $LGVN
    $OTRK
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Vice Chair Runkel Mark G. was granted 19,099 shares, increasing direct ownership by 20% to 116,827 units (SEC Form 4)

    4 - US BANCORP \DE\ (0000036104) (Issuer)

    2/12/26 4:48:36 PM ET
    $USB
    Major Banks
    Finance

    Vice Chair Richard Jodi L was granted 41,138 shares, increasing direct ownership by 20% to 247,790 units (SEC Form 4)

    4 - US BANCORP \DE\ (0000036104) (Issuer)

    2/12/26 4:47:35 PM ET
    $USB
    Major Banks
    Finance

    President & CEO Kedia Gunjan was granted 51,423 shares, increasing direct ownership by 16% to 375,321 units (SEC Form 4)

    4 - US BANCORP \DE\ (0000036104) (Issuer)

    2/12/26 4:46:32 PM ET
    $USB
    Major Banks
    Finance

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    U.S. Bancorp downgraded by Wolfe Research

    Wolfe Research downgraded U.S. Bancorp from Outperform to Peer Perform

    1/7/26 8:59:04 AM ET
    $USB
    Major Banks
    Finance

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Bancorp upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded U.S. Bancorp from Hold to Buy and set a new price target of $52.50

    10/23/25 7:00:20 AM ET
    $USB
    Major Banks
    Finance

    $EDBL
    $INVO
    $LGVN
    $OTRK
    SEC Filings

    View All

    Longeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    2/13/26 4:45:34 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Vanda Pharmaceuticals Inc.

    S-3 - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/12/26 7:17:54 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Vanda Pharmaceuticals Inc.

    10-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/12/26 7:04:07 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Kras James E. bought $2,050 worth of shares (3,700 units at $0.55), increasing direct ownership by 102% to 7,317 units (SEC Form 4)

    4 - Edible Garden AG Inc (0001809750) (Issuer)

    1/5/26 8:51:35 AM ET
    $EDBL
    Farming/Seeds/Milling
    Consumer Staples

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Bancorp Announces Leadership Changes in Its Operations Function

    Souheil Badran to retire from the company in April U.S. Bancorp (NYSE:USB), parent company of U.S. Bank, announced today that Souheil Badran, its senior executive vice president and chief operations officer, will retire from the bank this spring. "Souheil has led our operations function with distinction and a keen eye toward elevating our client experience with our contact centers and driving productivity and efficiency in service of our shareholders," said Gunjan Kedia, U.S. Bancorp chief executive officer. "I have appreciated his insights, advocacy and friendship, and we will build on the foundation he has helped set for the operations team." Badran joined the organization in late 2

    1/29/26 3:00:00 PM ET
    $USB
    Major Banks
    Finance

    U.S. Bancorp Appoints Gunjan Kedia Chairman of the Board of Directors Effective in April 2026

    Andy Cecere, current executive chairman, to retire from the Board of Directors at the Annual Meeting of Shareholders U.S. Bancorp (NYSE:USB), parent company of U.S. Bank, announced today that Gunjan Kedia, chief executive officer and president, has been appointed chairman of its Board of Directors, effective immediately following the annual meeting of shareholders in April 2026. Andy Cecere, the current executive chairman, will retire from the Board at that time; Roland Hernandez will continue in his role as the Board's lead independent director. "Gunjan is a remarkable leader who is well-respected by the Board, her team and our stakeholders for her strategic acumen, client focus and ab

    1/28/26 9:00:00 AM ET
    $USB
    Major Banks
    Finance

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Bancorp Reports Fourth Quarter 2025 Results

    U.S. Bancorp reported its fourth quarter 2025 results today. The earnings release, earnings supplement and slide presentation can be accessed online at ir.usbank.com/investor-relations/financial-information. At 8 a.m. Central Time, Chief Executive Officer Gunjan Kedia and Vice Chair and Chief Financial Officer John Stern will host a conference call to review the financial results. The conference call will be available online or by telephone. To access the webcast and presentation, visit U.S. Bancorp's website at usbank.com and click on "About Us," "Investor Relations", "News & events" and "Webcasts & Presentations." To access the conference call from locations within the United States and

    1/20/26 6:45:00 AM ET
    $USB
    Major Banks
    Finance

    $EDBL
    $INVO
    $LGVN
    $OTRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Edible Garden AG Incorporated

    SC 13G/A - Edible Garden AG Inc (0001809750) (Subject)

    11/14/24 7:24:20 PM ET
    $EDBL
    Farming/Seeds/Milling
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care